The modulation of subpopulations of pro-angiogenic monocytes (VEGFR-1+CD14 and Tie2+CD14) was analyzed in an ancillary study from the prospective PazopanIb versus Sunitinib patient preferenCE Study (PISCES) (NCT01064310), where metastatic renal cell carcinoma (mRCC) patients were treated with two anti-angiogenic drugs, either sunitinib or pazopanib. Blood samples from 86 patients were collected prospectively at baseline (T1), and at 10 weeks (T2) and 20 weeks (T3) after starting anti-angiogenic therapy. Various subpopulations of myeloid cells (monocytes, VEGFR-1+CD14 and Tie2+CD14 cells) decreased during treatment. When patients were divided into two subgroups with a decrease (defined as a >20% reduction from baseline value) (group 1) or not (group 2) at T3 for VEGFR-1+CD14 cells, group 1 patients presented a median PFS and OS of 24 months and 37 months, respectively, compared with a median PFS of 9 months (p = 0.032) and a median OS of 16 months (p = 0.033) in group 2 patients. The reduction in Tie2+CD14 at T3 predicted a benefit in OS at 18 months after therapy (p = 0.04). In conclusion, in this prospective clinical trial, a significant decrease in subpopulations of pro-angiogenic monocytes was associated with clinical response to anti-angiogenic drugs in patients with mRCC.
Cells. 2021 Dec 22*** epublish ***
Stephane Oudard, Nadine Benhamouda, Bernard Escudier, Patrice Ravel, Thi Tran, Emeline Levionnois, Sylvie Negrier, Philippe Barthelemy, Jean François Berdah, Marine Gross-Goupil, Cora N Sternberg, Petri Bono, Camillo Porta, Ugo De Giorgi, Omi Parikh, Robert Hawkins, Martin Highley, Jochen Wilke, Thomas Decker, Corinne Tanchot, Alain Gey, Magali Terme, Eric Tartour
APHP, Hôpital Européen Georges Pompidou, INSERM U970, PARCC, Université de Paris, 75020 Paris, France., Department of Medical Oncology, Institut Gustave Roussy, CEDEX, 94805 Villejuif, France., Cancer Bioinformatics and Systems Biology, Institut de Recherche en Cancérologie de Montpellier, Campus Val d'Aurelle, Université Montpellier, CEDEX 5, 34298 Montpellier, France., Centre Léon Bérard Lyon, University Lyon 1, 69008 Lyon, France., Institut de Cancérologie Strasbourg Europe, Strasbourg University Hospital, 67200 Strasbourg, France., Medical Oncology Unit, Hôpital Privé Toulon-Hyères, Sainte-Marguerite, 83400 Hyeres, France., Department of Medical Oncology, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, 31000 Bordeaux, France., Englander Institute for Precision Medicine, Weill Cornell Medicine, Sandra and Edward Meyer Cancer, New York, NY 10065, USA., Kamppi Hospital Department, Terveystalo Finland, 00100 Helsinki, Finland., Division of Translational Oncology, IRCCS San Matteo University Hospital, 27100 Pavia, Italy., IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, 47014 Meldola, Italy., Department of Oncology, Lancashire Teaching Hospitals NHS Foundation Trust, Preston PR2 9HT, UK., Institute of Cancer Sciences, University of Manchester, Manchester M13 9PL, UK., Oncology Centre, Derriford Hospital, Plymouth PL6 8DH, UK., Gemeinschaftspraxis Dres. Wilke/Wagner/Petzoldt, 90766 Fuerth, Germany., Studienzentrum Onkologie, Practice for Hematology and Oncology, 88212 Ravensburg, Germany.